Patients may be re-enrolled if they continue to need assistance and qualify for the Shire CARES PAP. The Shire CARES PAP has a simple enrollment process and offers free delivery of medicines for enrolled patients to their home or doctor's office for up to one year. The OnePath patient support team is committed to providing personalized, one-on-one product support services to help you access your prescribed Takeda treatment. "The program is designed to help patients with ulcerative colitis who are taking Lialda or Pentasa and are experiencing a financial hardship gain access to these treatments." "We are thrilled to launch this new, more robust program," said Mike Cola, president of the Specialty Pharmaceuticals business at Shire. The Lialda UC Support program offers patients the added benefit of hearing from professionals for medical insight and advice through an unbranded patient education Web site. Additionally, the Shire CARES PAP offers a discounted copay pharmacy card program and a 30-day free trial of Lialda when patients join the Lialda UC Support Program. Patient assistance programs (PAPs) are typically sponsored by pharmaceutical companies and offer cost-free or discounted medicines, as well as copay programs, to individuals with low income or those who are uninsured/under-insured and meet specific criteria. To be eligible for this program, you must: Be prescribed GAMMAGARD LIQUID for a condition its approved to treat by the Food. Patient Assistance & Copay Programs for Vyvanse. The Takeda Patient Support Co-Pay Assistance Program can cover up to 100 of your out-of-pocket co-pay costs, if your eligible. The new Shire CARES PAP includes job loss prescription coverage for 2009, and financial assistance at no cost and shared cost levels. We can direct you to programs that may help you save on your treatment, if your eligible. "Offering greater financial support to those who may be struggling due to the current economic climate through our expanded Shire CARES PAP is a natural extension of the Shire mission."Īccording to a recent press release from Shire, more than 100,000 people with UC have been treated with Lialda, and many have benefited from the Shire PAP. "We are committed to helping UC patients better manage their condition," said Roger Adsett, senior vice president of the GI business unit at Shire. This expands the existing Shire PAP to help even more uninsured patients and their families save on the medicines they need to stay healthy and to manage chronic conditions like UC. In addition, more UC patients can benefit from Lialda and Pentasa because Shire has raised the household income levels necessary to qualify for no cost and shared cost assistance. As a result of the recently enhanced Shire CARES PAP, UC patients who are newly prescribed or are already taking Lialda or Pentasa and who become unemployed in 2009 can receive their medication at no cost throughout the rest of the calendar year. Shire plc, the global biopharmaceutical company, is responding to the needs of patients who are diagnosed with ulcerative colitis (UC) and prescribed gastrointestinal (GI) medications from Shire by expanding its Patient Assistant Program (PAP).
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |